Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
Go back to Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026| (NASDAQ: CRDF) | Delayed: 1.30 +0.09 (7.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.21 | 52 Week High | $ | |||
| Open | $1.28 | 52 Week Low | $ | |||
| Day High | $1.43 | P/E | N/A | |||
| Day Low | $1.27 | EPS | $ | |||
| Volume | 1,069,943 | |||||
